Pixium Vision’s PRIMA Implanted in Five Patients with Atrophic Dry AMD

July 13, 2018: By Joan McKenna

Pixium VisionPixium Vision announced July 10 that the fifth and final patient in a feasibility trial in France has received the PRIMA subretinal implant, and the device has been successfully activated in the first four.

The wireless photovoltaic device is being evaluated in patients with severe vision loss from atrophic dry age-related macular degeneration (AMD).

The first four subjects were able to perceive light patterns in areas where previously there was no remaining perception, the Paris company said. The device will be activated in the fifth patient soon.

The implant is 2 mm by 2 mm and 30 microns thick, equipped with 378 electrodes. A mini-camera and glasses power the implant.

Six-month interim results will be available by the end of 2018, allowing Pixium to prepare for a larger European pivotal study to obtain CE marking, the company said.

In addition, Pixium’s feasibility study in the US is active at the University of Pittsburgh Medical Center. The company expects the first US implantations to take place in Q3-2018.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

CMS Allows Medicare Advantage Plans to Apply Step Therapy to Retinal Injections

Glaukos Reports Drug Collaboration with D. Western, Q2-2018 Net Sales Increase of 5 Percent

Allergan Will Co-develop Editas’ CRISPR Genome Editing Candidate for LCA10

Spark Reports Q2-2018 Net Sales of $4.3 Million for Luxturna

Aerie’s Rhopressa Posts $2.4 Million in Net Revenues in Q2-2018

Astellas Acquires Quethera, Glaucoma Gene Therapy Candidate in Potential $109 Million Deal

STAAR Surgical Completes $77.9 Million Public Offering

Rheon’s eyeWatch Adjustable Glaucoma Device Implanted in Three UK Patients

Carl Zeiss Meditec Revenues Total $356 Million in Third Quarter of FY2018, a 12.7 Percent Increase

Kedalion Therapeutics Raises $5 Million in Series A Financing

Second Sight Reports 17 Argus II Implantations in Q2-2018; Firm to Focus on Orion System

Iridex Revenues Grow 3 Percent in Q2-2018

Omeros Revenues Drop Steeply with Omidria’s Temporary Loss of Pass-through Status

Shire’s Xiidra Delivers $100 Million in Q2-2018 Revenues, an Increase of 75 Percent

STAAR Posts Q2-2018 Revenues of $33.9 Million, a 55 Percent Increase

Avedro Names Glaukos CEO Thomas Burns to its Board

Aerie Licenses DSM’s Bioerodible Implant Technology for Ophthalmic Use for $15 Million

Alimera’s Q2-2018 Revenues Increase 5 Percent

Presbyopia Therapies’ PRX Meets Phase IIb Endpoints

Clinical Study of Imprimis’ Dropless Formulation Set to Begin in Canada

Coming soon

2018 Ophthalmic Laser Report: A Global Market Analysis for 2017 to 2023 (Photocoagulation, Photodisruption, and SLT